Media – Nacuity Pharmaceuticals

Press Releases

June 15, 2022

Press Release: "Nacuity Pharmaceuticals Announces $16.5 Million Series B Financing Led by Foundation Fighting Blindness & RD Fund"

Nacuity Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing treatments for retinitis pigmentosa, cataracts and other ocular diseases caused by oxidative stress, today announced the closing of a $16.5 million Series B financing led by Foundation Fighting Blindness and its venture arm RD Fund. Additional existing investors also participated in the round. Maxim Merchant Capital, a division of Maxim Group LLC, served as sole placement agent for the financing. Read more...

June 8, 2022

Press Release: "Nacuity Pharmaceuticals Strengthens Scientific Advisory Board with Appointment of Nancy Holekamp, M.D., and Richard L. Lindstrom, M.D."

Nacuity Pharmaceuticals, Inc. (Nacuity) today announced the expansion of its Scientific Advisory Board (SAB) with the appointment of Nancy Holekamp, M.D., and Richard L. Lindstrom, M.D. Read more...

August 13, 2021

Press Release: "Integral BioSystems and Nacuity Pharmaceuticals Ink Collaboration and License Deal"

Drug delivery technology firm Integral Biosystems and Nacuity Pharmaceuticals, Inc. have signed a Collaboration and License Agreement to co-develop sustained release products utilizing Nacuity’s proprietary antioxidant compounds and Integral’s patented NanoM™ platform ophthalmic insert technology. Under the collaboration, Nacuity and Integral will develop products to treat several ocular disorders.

March 31, 2021

Press Release: "Nanoform and Nacuity Pharmaceuticals Sign Technology Proof of Concept ("PoC") Agreement for Two Ophthalmic Drug Candidates"

Nanoform Finland Plc, an innovative nanoparticle medicine enabling company, and Nacuity Pharmaceuticals Inc. today announced that they have signed a Technology Proof of Concept ("PoC") Agreement, with compensation on standard commercial terms. This will apply Nanoform's award-winning nanoparticle CESS® technology to enhance ophthalmic drug delivery of Nacuity's NPI-001 and NPI-002 drug candidates.

May 18, 2020

Press Release: "Nacuity Pharmaceuticals Announces Initiation of SLO-RP (Safety and Efficacy of NPI-001 Tablets versus PLacebO for Treatment of Retinitis Pigmentosa Associated with Usher Syndrome) Phase 1/2 Clinical Trial "

Nacuity Pharmaceuticals, Inc. (Nacuity) today announced the initiation of a Phase 1/2 study of NPI-001 tablets in patients with retinitis pigmentosa (RP) associated with Usher syndrome (USH). The study, named SLO-RP, is designed to demonstrate greater retinal sensitivity in RP/USH patients treated with NPI-001 Tablets versus placebo. Read more...

June 13, 2018

Press Release: "Nacuity Pharmaceuticals, Inc., and Johns Hopkins Sign Exclusive License Agreement to Advance Treatment of Retinitis Pigmentosa"

Nacuity Pharmaceuticals, Inc. (Nacuity) announces that it has entered into an agreement with Johns Hopkins University (JHU) providing Nacuity with an exclusive worldwide license to the intellectual property (IP) underlying certain U.S. and foreign patent applications that Nacuity has filed in collaboration with the Johns Hopkins Wilmer Eye Institute. Read more...

January 18, 2017

Press Release: "Foundation Fighting Blindness Supporting Clinical Development of NACA, Promising New Drug for Many Forms of RP"

The Foundation Fighting Blindness, the leading charitable institution driving research to provide treatments for people affected by RP and AMD, issues a press release announcing its technical and financial support of Nacuity Pharmaceuticals.

News

August 24, 2021

"New Trial for Usher Syndrome Vision Loss"

This story from the Centre for Eye Research Australia (CERA) shares a family's experience with a child living with Usher syndrome, and their hopes for the Nacuity-sponsored study Safety and Efficacy of NPI-001 Tablets versus Placebo for Treatment of Retinitis Pigmentosa Associated with Usher Syndrome (SLO RP).

May 21, 2020

"Nacuity’s Emerging Anti-Oxidative Therapy Moves into Clinical Trial"

This post from the The Foundation Fighting Blindness announces that Nacuity is launching a Phase 1/2 clinical trial in Australia for NPI-001, an oral treatment designed to slow vision loss in people with retinitis pigmentosa (RP) and RP associated with Usher syndrome.

October 25, 2017

"Will Adelaide Make a Better Living Through Chemistry? Inside SA’s Biomedical Boom"

Nacuity Pharmaceuticals is featured in an article in The Adelaide Review as one of the pharmaceutical companies taking advantage of the financial and regulatory incentives provided by Adelaide, Australia, to bring clinical trials to their city.

September 27, 2017

"FFB’s Investments Are Filling the Pipeline for Vision-Saving Therapies"

Nacuity Pharmaceuticals CEO Halden Conner presented the company’s emerging drug N-Acetylcysteine Amide (NACA) at The Foundation Fighting Blindness' "Investing in Cures Summit" in Chicago, Illinois.

January 19, 2017

"Foundation Investing in Drug to Slow Many Forms of RP"

This post from the The Foundation Fighting Blindness' blog "Eye on the Cure" describes its investment in Nacuity Pharmaceuticals to advance RP treatment.

Publications

June 16, 2022

“Evaluation of NACA and diNACA in Human Cystinosis Fibroblast Cell Cultures as Potential Treatments for Cystinosis”

Hector E, Cairns D, Michael Wall G. Evaluation of NACA and diNACA in human cystinosis fibroblast cell cultures as potential treatments for cystinosis. Orphanet J Rare Dis. 2022 Jun 16;17(1):231. doi: 10.1186/s13023-022-02367-w. PMID: 35710564.

October 26, 2020

“Antioxidant Effects of N-acetylcysteine Amide and NPI-002 on Human Skin or Equivalents.”

Neil J; Wall GM; Brown M. Antioxidant Effects of N-acetylcysteine Amide and NPI-002 on Human Skin or Equivalents. AAPS PharmSci360, Poster Abstract, October 26-November 5, 2020.

January 23, 2019

"Quantitation of Free and Total N-acetylcysteine Amide and Its Metabolite N-acetylcysteine in Human Plasma using Derivatization and Electrospray LC-MS/MS"

King B; Vance J; Wall GM; Shoup R. Quantitation of free and total N-acetylcysteine amide and its metabolite N-acetylcysteine in human plasma using derivatization and electrospray LC-MS/MS. J Chrom B 2019;1109:25-36.